Allianz Asset Management
CASC

Allianz Asset Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Allianz Asset Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-30,258
Closed -$588K – 2407
2014
Q2 		$588K Sell
30,258
-3,125
-9% -$55.1K ﹤0.01% 1542
2014
Q1 		$599K Hold
33,383
– – ﹤0.01% 1545
2013
Q4 		$353K Hold
33,383
– – ﹤0.01% 1616
2013
Q3 		$413K Hold
33,383
– – ﹤0.01% 1557
2013
Q2 		$314K Buy
+33,383
New +$429K ﹤0.01% 1557

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM

Allianz Asset Management's CASC Position: Q3 2014 in Review

Allianz Asset Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2014, closing a stake of 30,258 shares — an estimated $588K sold.

Allianz Asset Management first reported a position in CASC in Q2 2013 and held it in 5 quarters. The position peaked at $599K in Q1 2014. 86 funds tracked by Wall St. Rank hold CASC as of Q3 2014.

  • Allianz Asset Management reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
  • Allianz Asset Management sold 30,258 Cascadian Therapeutics, Inc. shares in Q3 2014, an estimated $588K.
  • Allianz Asset Management first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 5 quarters.
  • Allianz Asset Management's Cascadian Therapeutics, Inc. position peaked at $599K in Q1 2014.
  • 86 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2014.

Based on Allianz Asset Management's 13F filing for Q3 2014, filed 14 Nov 2014.